Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-28
2010-12-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S275000, C544S122000, C544S295000, C544S331000
Reexamination Certificate
active
07855205
ABSTRACT:
The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I)and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.
REFERENCES:
patent: 2004/0097506 (2004-05-01), Thomas
patent: 2005/0107384 (2005-05-01), Angibaud et al.
patent: 2007/0043048 (2007-02-01), Bollbuck et al.
patent: WO 0114375 (2001-03-01), None
patent: WO 02079193 (2002-10-01), None
patent: WO 02102783 (2002-12-01), None
patent: WO 03011836 (2003-02-01), None
patent: WO 03011837 (2003-02-01), None
patent: WO 03051886 (2003-06-01), None
patent: WO 03/092686 (2003-11-01), None
patent: WO 2004005282 (2004-01-01), None
patent: WO 2004005283 (2004-01-01), None
patent: WO 2005/095400 (2005-10-01), None
Bollbuck et al., CAPLUS Abstract 141:379931, 2004.
Traxler, Protein Kinase inhibitors in cancer treatment, Expert Opinion on Therapeutic Patents, 7(6), pp. 571-588, 1997.
Lu Valle et al., Cell Cycle Control in Growth Plate Chondrocytes, Frontiers in Biosciences 5, d493-503, May 2000.
Blain et al., Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4, The Journal of Biological Chemistry, vol. 272, No. 41, pp. 25863-25872, Oct. 1997.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Doublas, Jr., Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
International Search Report re: PCT/US05/38905 dated Apr. 13, 2006.
X. Wang, et al., “Epidermal Growth Factor Receptor is A Cellular Receptor for Human Cytomegalovirus,”Nature, Jul. 24, 2003, vol. 424.
K. Nasmyth, “Viewpoint: Putting The Cell Cycle in Order,”Science, vol. 274 (1996) p. 1643-1677.
D. O. Morgan, “Cyclin-Dependent Kinases: Engines, Clocks, and Microprocessors,”Annu.Rev Cell Dev. Biol., vol. 13 13 (1997), p. 261-291.
J. Lukas, et al., “Cyclin E-induced S Phase Without Activation of The pRb/E2F Pathway,”Genes and Dav., vol. 11 (1997), p. 1479-1492.
J.W. Harper, “Cyclin Dependent Kinase Inhibitors,”Cancer Surv., vol. 29 (1997), p. 91-107.
M. Hall, et al., “Genetic Alerations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer,”Adv. Cancer Res., vol. 68 (1996), p. 67-108.
A. Kamb, et al., “A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types,”Science, vol. 264 (1994), p. 436-440.
G. Delsal, et al., “Cell Cycle and Cancer: Critical Events at The G1 Restriction Point,”Critical Rev. Oncogenesis, vol. 71 (1996), p. 127-142.
R. Ross, “The Pathogenesis of Atherosclerosis: A Perspective for The 1990's,”Nature, 1993, 362, p. 801-809.
G. L. Wei, et al., “Temporally and Spatially Coordinated Expression of Cell Cycle Regulatory Factors after Angioplasty,”Circ. Res., (1997), 80, p. 418-426.
E. E. Brooks, “CVT-313, A Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation,”J. Biol. Chem., (1997), 272(46): p. 29207-29211.
Connolly Peter J.
Emanuel Stuart L.
Huang Shenlin
Li Ronghua
Middleton Steven A.
Janssen Pharmaceutica NV
Rao Deepak
LandOfFree
Pyrimidinyl substituted fused-pyrrolyl compounds useful in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidinyl substituted fused-pyrrolyl compounds useful in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidinyl substituted fused-pyrrolyl compounds useful in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185916